Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer.
- Author:
Yong Tai KIM
1
;
Joo Hyuk SOHN
;
So Hun KIM
;
Sun Young RHA
;
Chul KIM
;
Jae Kyung ROH
;
Byung Soo KIM
;
Woo Ick JANG
;
Hyun Cheol CHUNG
Author Information
1. Cancer Metastasis Reserch Center, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Stomach neoplasm;
Combination Chemotherapy;
Infusional 5-FU;
Leucovorin;
Docetaxel
- MeSH:
Anemia;
Diarrhea;
Drug Therapy;
Drug Therapy, Combination;
Fluorouracil*;
Humans;
Leucovorin*;
Mucositis;
Nausea;
Neutropenia;
Stomach Neoplasms*;
Vomiting
- From:Cancer Research and Treatment
2003;35(2):123-129
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma. MATERIALS AND METHODS: Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1, 000 mg/m2 intravenous (IV) 24 hour infusion (Day 1~3), leucovorin 20 mg/m2 (Day 1~3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks. RESULTS: The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4~24), the median time to response was 8 weeks (range: 8~20) the median time to progression was 30.0 weeks (95% CI: 16.3~43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7~70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity. CONCLUSION: This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients.
